On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route. It reads as pedantry until the day it does not.
Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below.
Reading back through what has been written here about oral semaglutide, three questions come up every time and only one has ever been answered properly.
Listing all three, with what I think the state of the answer is for each, so the thread can start further along than the last one did.
I read the opening post twice before replying, because I had assumed the opposite.
Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.
On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.
It reads as pedantry until the day it does not.
I would put moderate confidence on the mainstream reading of oral semaglutide and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
Building on post #5 rather than restating it.
SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.
Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.
It is a small point and it changes the answer, which is an awkward combination.
Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.
This has been discussed before and I could not find the thread, so, again.
On post #5 — agreed on the reasoning, with one qualification.
Timing consistency matters more for oral dosing than for weekly injection, because absorption depends on the state of the stomach and the state of the stomach varies through the day.
Reading rather than answering, but this is the post I would point somebody at.
Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.
Where I have landed on oral semaglutide, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.
Building on post #11 rather than restating it.
Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.
I would treat the number as indicative rather than as a measurement.
Post #12 put the caveat in the right place and I want to underline it.
Tablet integrity matters more than people expect for a formulation that depends on an absorption enhancer released at a particular place. Splitting or crushing is not a dose adjustment; it is a different product.
The rule of thumb is fine; the edge cases are where it earns its keep.
Narrowing post #14, because the general version has more than one answer.
Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low enough that dose numbers are an order of magnitude different and not directly comparable.
That is where I would start, not where I would stop.
Grateful for the specificity. Vague answers to this question are what sent me looking.
Before the thread moves on from oral semaglutide — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
Post #17 and I disagree about the size of the effect, not about the direction.
Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.
This is the version I would want a new member to read first.
The absorption enhancer in the licensed oral product works by transiently raising local gastric pH and promoting absorption across the mucosa. It is the reason the fasting and water-volume instructions are specific rather than cautious.
A weak preference rather than a position.
I read post #17 twice before replying, because I had assumed the opposite.
Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning absorption-enhancement system at all. The formulation is most of the product here.
That matches what I was told, which is not the same as knowing it.
Worth separating two things that post #17 runs together.
The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.
Noting that I have skin in this question and have tried to discount for it.
This follows post #21 rather than contradicting it.
The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.
Adding the caveat now so it does not have to be extracted later.
Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of peptide synthesis, different analytical methods entirely. Data from peptide agonists does not transfer.
A small molecule can be characterised by nuclear magnetic resonance and by mass spectrometry against a reference standard, which is a considerably stronger identity claim than a peptide chromatogram usually supports.
Post #21 and I disagree about the size of the effect, not about the direction.
Two people in this thread mean different things by oral semaglutide and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.
The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.
I would rather be precise about what I do not know than vague about what I do.
Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.
Taking oral semaglutide seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.